Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Renata Talar‐Wojnarowska

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3887-2712; OpenAlex author ID A5017329070. Sources: OpenAlex.

Their work

Papers
40 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
92
Papers, trials and grants by year

2013: 4 papers · 2014: 2 papers · 2015: 1 paper · 2016: 5 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 6 papers · 2022: 1 paper · 2023: 6 papers · 2024: 2 papers · 2025: 2 papers

Papers 40

  1. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  2. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  3. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  4. Select Endocrine Disorders and Exosomes in Early PDAC Diagnosis. Co-author DOI 10.3390/ijms252212159↗
  5. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  6. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  7. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  8. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  9. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  10. CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation. Co-author DOI 10.3390/jcm12124050↗
  11. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  12. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  13. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  14. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  15. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  16. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  17. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  18. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  19. Clinical significance of activin A and myostatin in patients with pancreatic adenocarcinoma and progressive weight loss. Co-author DOI 10.26402/jpp.2020.1.10↗
  20. Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma. Co-author DOI 10.3390/medicina56120677↗
  21. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  22. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  23. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  24. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. First author DOI 10.5114/pg.2019.83422↗
  25. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  26. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  27. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  28. Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Co-author DOI 10.1158/1055-9965.epi-17-0075↗
  29. Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer. First author DOI 10.1007/s10620-015-3972-6↗
  30. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  31. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  32. Analysis of XRCC2 and XRCC3 gene polymorphisms in pancreatic cancer. Co-author DOI 10.3892/br.2015.550↗
  33. Utility of different serum fibrosis markers in diagnosing patients with chronic pancreatitis and pancreatic adenocarcinoma. First author DOI 10.4251/wjgo.v8.i8.635↗
  34. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  35. Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1016/j.advms.2014.08.003↗
  36. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Last author DOI 10.1038/ng.3052↗
  37. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  38. Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer. First author DOI 10.1016/j.pan.2013.04.198↗
  39. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  40. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ewa I. Malecka-Panas · 14 shared papers, 2013–2024 · strength 1.32
  2. Łukasz Durko · 2 shared papers, 2023–2024 · strength 0.52
  3. Barbara Włodarczyk · 2 shared papers, 2023–2024 · strength 0.52
  4. Federico Canzian · 10 shared papers, 2013–2022 · strength 0.51
  5. Gabriele Capurso · 10 shared papers, 2013–2022 · strength 0.51
  6. Daniele Campa · 10 shared papers, 2013–2022 · strength 0.51
  7. Francesca Tavano · 8 shared papers, 2013–2022 · strength 0.46
  8. John P. Neoptolemos · 8 shared papers, 2013–2022 · strength 0.43
  9. Pavel Souček · 8 shared papers, 2013–2022 · strength 0.41
  10. Raffaele Pezzilli · 8 shared papers, 2013–2022 · strength 0.41
  11. Marek Olakowski · 4 shared papers, 2014–2020 · strength 0.39
  12. Maria Gazouli · 7 shared papers, 2013–2022 · strength 0.37
  13. Anita Gąsiorowska · 6 shared papers, 2013–2019 · strength 0.36
  14. Thilo Hackert · 6 shared papers, 2016–2021 · strength 0.34
  15. Oliver Strobel · 6 shared papers, 2016–2021 · strength 0.34
  16. Beatrice Mohelníková-Duchoňová · 6 shared papers, 2013–2022 · strength 0.32
  17. Rita Teresa Lawlor · 5 shared papers, 2017–2022 · strength 0.31
  18. Pavel Vodička · 6 shared papers, 2013–2021 · strength 0.27
  19. Giulia Martina Cavestro · 3 shared papers, 2019–2022 · strength 0.25
  20. Manuel Gentiluomo · 3 shared papers, 2019–2022 · strength 0.25
  21. Eithne Costello · 5 shared papers, 2013–2021 · strength 0.25
  22. Daniela Basso · 4 shared papers, 2013–2022 · strength 0.22
  23. Stefano Landi · 6 shared papers, 2013–2018 · strength 0.22
  24. Ľudmila Vodičková · 5 shared papers, 2013–2022 · strength 0.21
  25. Paweł Lampe · 3 shared papers, 2014–2019 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.